Generic Drugs and Preemption in the Wake of Wyeth v. Levine


There is a rapidly growing split of authority among courts as to whether FDA regulation of generic drug labeling preempts state-law failure-to-warn claims. This article examines the continuing viability of a preemption defense in pharmaceutical product liability cases alleging the defective labeling of generic drugs in the wake of Levine.

LOADING PDF: If there are any problems, click here to download the file.

Published In: Civil Procedure Updates, Products Liability Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Kelly Savage Day | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »